TrialPath
Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924 · Servier
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
About this study
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC, GI tumors (including ColoRectal Cancer (CRC), and non-CRC GI adenocarcinoma, and Biliary Tract Cancer (BTC)) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28 or 21-days cycles (depending on the study part they are included in) until disease progression, toxicity, withdrawal of consent, or termination of the study.
Eligibility criteria
Key Inclusion Criteria: * Life expectancy of ≥ 12 weeks in the opinion of the investigator. * Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations. * Adequate bone marrow and organ function. * Recovered from toxicity to prior anti-cancer therapy. Part 1 Dose Escalation cohort ONLY: * Part 1A: Advanced/metastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations * Part 1B: Advanced/metastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations * Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations * Part 1E: Other advanced/metastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations * Part 1F: Solid tumors with BRAF or NRAS mutations or alterations * Part 1G: Solid tumors with BRAF or NRAS mutations or alterations Part 2 Dose Optimization and Expansion cohorts ONLY: * Part 2A: Advanced/metastatic NSCLC with BRAF mutations or alterations * Part 2A2: Advanced/metastatic NSCLC with BRAF mutations or alterations * Part 2B2: Advanced/metastatic CRC with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations * Part 2B3: Advanced/metastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations * Part 2B4: Advanced/metastatic non-CRC GI cancer (adenocarcinoma) with KRAS mutations or alterations * Part 2D1: Advanced/metastatic CRC (adenocarcinoma) with BRAF mutations or alterations * Part 2F: Advanced/metastatic tumor type with KRAS non-G12C, and/or BRAF mutations or alterations Key Exclusion Criteria: * Cancer that has a known MEK1/2 mutation. * Known allergy/hypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination. * Any contraindication, to the use of any of the combination agents administered as part of the assigned cohort, including failure to meet the regimen-specific ANC requirements * Major surgery within 4 weeks of study entry or planned during study. * Ongoing anticancer therapy. * Ongoing radiation therapy. * Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy. * Clinically significant cardiovascular disease. * Symptomatic spinal cord compression. * Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years. * History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO. * Females who are pregnant or breastfeeding. * Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study. * Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway. * Part 1F: Any ocular abnormality, active myositis or myopathy or history of rhabdomyolysis, or severe dermatologic condition * Part 1G: Active autoimmune disease, severe dermatologic condition, or systemic treatment with corticosteroids
Study design
Enrollment target: 623 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2023-04-18
Estimated completion: 2028-06
Last updated: 2026-11-17
Interventions
Drug: S241656Drug: FOLFOX6/FOLFOX7Drug: FOLFIRIDrug: CetuximabDrug: PanitumumabDrug: TrametinibDrug: Pembrolizumab
Primary outcomes
  • • Dose Escalation: Incidence of dose-limiting toxicities (DLTs) (The first 28-day cycle (Cycle 1))
  • • Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) (Through study completion, approximately 5 years)
  • • Dose Optimization/Expansion: Objective response (OR) (Through study completion, approximately 5 years)
Sponsor
Institut de Recherches Internationales Servier · other
Contacts & investigators
ContactInstitut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department · contact · scientificinformation@servier.com · +33 1 55 72 60 00
All locations (49)
Banner Health- MD Anderson Cancer CenterRecruiting
Gilbert, Arizona, United States
The Angeles clinic - A cedars SINAI AFFILIATERecruiting
Los Angeles, California, United States
USC Norris Comprehensive Cancer CenterRecruiting
Los Angeles, California, United States
University of California, San Francisco (UCSF)Recruiting
San Francisco, California, United States
University of Colorado - Aurora Cancer CenterNot Yet Recruiting
Aurora, Colorado, United States
Yale University School of Medicine - Yale Cancer CenterRecruiting
New Haven, Connecticut, United States
Georgetown University Lombardi Cancer CenterNot Yet Recruiting
Washington D.C., District of Columbia, United States
Sibley Memorial HospitalRecruiting
Washington D.C., District of Columbia, United States
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
South Texas Accelerated Research Therapeutics (START) MidwestRecruiting
Grand Rapids, Michigan, United States
Masonic Cancer Center University of MinnesotaRecruiting
Minneapolis, Minnesota, United States
Washington UniversityRecruiting
St Louis, Missouri, United States
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)Recruiting
New York, New York, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
Duke University School of MedicineRecruiting
Durham, North Carolina, United States
Cleveland ClinicRecruiting
Cleveland, Ohio, United States
Sarah Canon Research Institute (SCRI) Oncology PartnersRecruiting
Nashville, Tennessee, United States
MD Anderson Cancer CenterRecruiting
Houston, Texas, United States
START San AntonioRecruiting
San Antonio, Texas, United States
NEXT VirginiaRecruiting
Fairfax, Virginia, United States
Fred Hutchinson Cancer Research CenterRecruiting
Seattle, Washington, United States
Peter MacCallum Cancer CentreNot Yet Recruiting
East Melbourne, Australia
Westmead HospitalNot Yet Recruiting
Westmead, Australia
Beijing Cancer HospitalRecruiting
Beijing, China
Shandong Cancer Hospital (Cancer Hospital of Shandong First Medical University)Recruiting
Jinan, China
Fudan University Zhongshan HospitalNot Yet Recruiting
Shanghai, China
The Second Affiliated Hospital of Soochow UniversityRecruiting
Suzhou, China
Center for Cancer and Organ Diseases - RigshospitaletRecruiting
Copenhagen, Denmark
Centre Georges Francois LeclercNot Yet Recruiting
Dijon, France
Institut CurieRecruiting
Paris, France
AP-HP Hopital Europeen Georges PompidouRecruiting
Paris, France
Centre Eugene MarquisRecruiting
Rennes, France
Institut Gustave RoussyNot Yet Recruiting
Villejuif, France
Queen Mary HospitalRecruiting
Hong Kong, Hong Kong
Prince of WalesRecruiting
Shatin, Hong Kong
Istituto Europeo di OncologiaNot Yet Recruiting
Milan, Italy
IFO - Istituto Nazionale dei Tumori Regina ElenaNot Yet Recruiting
Rome, Italy
Istituto Clinico HumanitasRecruiting
Rozzano, Italy
Kanagawa Cancer CenterRecruiting
Kanagawa, Japan
Kyoto University HospitalRecruiting
Kyoto, Japan
National Cancer Center HospitalRecruiting
Tokyo, Japan
Hospital Universitario Vall d'HebronNot Yet Recruiting
Barcelona, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez DiazRecruiting
Madrid, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCCRecruiting
Madrid, Spain
Clinica Universidad de Navarra - PamplonaRecruiting
Pamplona, Spain
Hospital Clinico Universitario de ValenciaRecruiting
Valencia, Spain
University College London HospitalRecruiting
London, United Kingdom
Hammersmith HospitalRecruiting
London, United Kingdom
The Christie NHS Foundation TrustRecruiting
Manchester, United Kingdom